Abstract
AbstractThe anti‐human bladder cancer monoclonal antibody BDI‐1 was radio‐labeled with rhenium‐188 by direct labeling methods using SnCl2 as reductant and MDP as stannous stabilizer or by indirect method using NHS‐ECM ester as bifunctional chelator. Radiochemical yields of 30±7.23% and 87.4±5.67% and radiochemical purity of more than 95% were achieved. The inmmunoreactive fraction was 58.7%. The results showed that radionuclide 188Re might be employed using the same labeling methodology with 99mTc labeling of BDI‐1 for radiommunoimaging (RII) and radioimmunotherapy (RIT) and that may be useful in radioimmunodetection and RIT of human bladder carcinoma in vivo. Copyright © 2001 John Wiley & Sons, Ltd.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
